Research Paper Volume 15, Issue 23 pp 13753—13775
PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study
Figure 5. Immune-related analysis of WDR72 in TCGA and Nivolumab-treated ccRCC cohorts. (A) The correlation between WDR72 expression and infiltration level of immune cells in ccRCC from TCGA database. (B) The scatterplot showing Spearman correlation between WDR72 expression and the ssGSEA score of Treg cell in ccRCC from TCGA database. (C) Comparison of the ssGSEA scores of Treg cell between the WDR72-high and WDR72-low groups in TCGA dataset. (D) Heatmap of the ssGSEA scores integrating the tumor purity, ESTIMATE score, immune score, and stromal score of each sample between the WDR72-high and WDR72-low groups in Nivolumab-treated ccRCC patients from Checkmate 009, 010 and 025. The scatterplot showing Spearman correlation between WDR72 expression and the ssGSEA score of (E) Treg cell or (F) check-point in Nivolumab-treated ccRCC patients. Comparison of the ssGSEA scores of (G) Treg cell and (H) check-point between the WDR72-high and WDR72-low groups in Nivolumab-treated ccRCC patients. (I) Correlation analyses among WDR72, pivotal genes of fatty acid beta oxidation, and Treg cell signature genes in Nivolumab-treated ccRCC patients. Abbreviations: Treg cell, Regulatory T cell; ssGSEA, single sample Gene Set Enrichment Analysis. * P <0.05, ***P <0.001.